<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
<LINK rel="stylesheet" type="text/css" href="../Assets/Be.css">
<META NAME="contextstring" CONTENT="Antihypertensivetreatmentmayhavereducedtherateofdementiainolderpatientswithisolatedsystolichypertension">
<META NAME="keywords" CONTENT="Alzheimer's disease;Antihypertensive treatment;Apoplexy;Arterial hypertension;Atherosclerotic dementia;Binswanger's encephalopathy;Blood pressure;Blood pressure, high;Calcium channel blockers;Cardiac index;Cerebral hemorrhage;Cerebral infarct;Cerebrovascular accident;Cerebrovascular events;Chronic hypertension;Chronic progressive subcortical encephalopathy;CI;Completed stroke;CVA - cerebral infarction;CVA - cerebrovascular accident;DAT - dementia alzheimer's type;Dementia;Dementia, multiinfarct;Dementia, senile;Diastolic blood pressure;Dichlothiazide;Dihydrochlorothiazide;Electron gain;Enalapril;Essential hypertension;HCTZ;Hemorrhagic stroke;High blood pressure;HTN;Hydrochlorothiazide;Hyperpiesis;Hypertension;Hypothiazide;Idiopathic hypertension;Intentions;Intracerebral hemorrhage;Intracranial hemorrhage;Isolated systolic hypertension;Mental illness;Multi-infarct dementia;Old age, dementia of;Oretic;Primary degenerative dementia;Primary hypertension;Psychiatric disorders;Resting blood pressure;Resting pressure;Safety;SDAT;Sectrazide;Senile dementia;Stroke;Stroke incidence;Subcortical dementia;Systemic blood pressure;Systemic primary arterial hypertension;Systolic blood pressure;Systolic hypertension;Treatment of high blood pressure;Uncontrolled hypertension;Vascular dementia">
<META NAME="groups" CONTENT="BE99:0400;BE;Therapeutics">
<META HTTP-EQUIV="Content-Type" Content="text-html; charset=Windows-1252">
<title>Grossman 2000</title>
</HEAD>
<BODY BGCOLOR=#FFFFFF TEXT=#000000>
<P CLASS="BEsection">Therapeutics</p>
<P CLASS="AbsTitl"><B><font size="4"><a name="antihypertensivetreatmentmayhavereducedtherateofdementiainolderpatientswithisolatedsystolichypertension"></a><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000><font 
      class=pageboldgrn color=#009982><font 
      class=abstitle><b><font color="#333333">Review: Intensive blood-pressure 
  control and drugs reduce morbidity and mortality in hypertension and diabetes 
  mellitus</font></b></font></font></font></font></B></p>
<p><font class="textblack" color="#333333"><font 
      class=pageboldgrn><b><font face="Arial, Helvetica, sans-serif" size="3">ACP 
  Journal Club. 2001 Mar-Apr;134:48.</font></b></font></font></p>
<p><font class="sourcecitation" face="Arial, Helvetica, sans-serif" size="3">Grossman 
  E, Messerli FH, Goldbourt U. <b>High blood pressure and diabetes mellitus. Are 
  all antihypertensive drugs created equal?</b> Arch Intern Med. 2000 Sep 11;160:2447-52.</font></p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="AbsHd">Question</p>
<P CLASS="AbsTxt"><font class=textblack color=#000000><font class="pageboldgrn">In 
  patients with hypertension and diabetes mellitus, what is the effectiveness 
  of various antihypertensive treatments?</font></font></p>
<P CLASS="AbsHd">Data sources</p>
<p class=abstxt><font class="textblack" color="#000000">Studies were identified 
  by searching MEDLINE (to June 1999) with the terms diabetes mellitus, hypertension, 
  blood pressure, treatment, and therapy. Bibliographies of relevant studies were 
  also checked.</font><font class="textblack" color="#000000" size="2"></font></p>
<p></p>
<P CLASS="AbsHd">Study selection</p>
<p class=abstxt><font class="textblack" color="#000000">English-language studies 
  were selected if they were randomized controlled trials &gt; 12 months of duration 
  that compared the effects of active drug treatments with placebo on morbidity 
  and mortality in patients with hypertension and diabetes mellitus. </font><font class="textblack" color="#000000" size="2"> 
  </font></p>
<P CLASS="AbsHd">Data extraction</p>
<p class=abstxt><font class="textblack" color="#000000">Data were extracted on 
  patient characteristics, follow-up period, blood pressure, rate of patients 
  continuing to receive monotherapy, and cardiovascular morbidity and mortality. 
  </font></p>
<P CLASS="AbsHd">Main results</p>
<p class=abstxt><font class="textblack" color="#000000">8 studies (5244 patients) 
  met the selection criteria. 3 studies compared 2 active treatments, 1 study 
  reported the effects of intensive blood-pressure lowering, and 3 studies compared 
  active treatment with placebo. In 6 studies, mean ages ranged between 55 and 
  71 years; in 2 studies, patients were &gt;60 years of age. Follow-up duration 
  ranged between 2 and 8 years. Intensive blood-pressure control reduced cardiovascular 
  morbidity and mortality. One study showed that the calcium antagonist nisoldipine 
  increased the incidence of fatal or nonfatal myocardial infarction more than 
  did the angiotensin-converting enzyme (ACE) inhibitor enalapril maleate (11% 
  vs 2%, relative risk increase 4%, 95% CI 1 to 11, number needed to harm 12, 
  CI 7 to 23). In the 3 studies that compared active treatment with placebo, a 
  diuretic (chlorthalidone) and a calcium antagonist (nitrendipine) reduced cardiac 
  end points, stroke, and total mortality. Comparisons between antihypertensive 
  drugs were not possible because study populations differed. Except for nisoldipine, 
  adverse events did not differ among drugs. </font></p>
<P CLASS="AbsHd">Conclusion</p>
<p class=abstxt><font class="textblack" color="#000000">Intensive blood-pressure 
  control reduces cardiovascular morbidity and mortality in patients with hypertension 
  and diabetes mellitus regardless of which of 4 classes of antihypertensive drugs 
  (low-dose diuretics, Î²-blockers, ACE inhibitors, and calcium antagonists) is 
  used as first-line therapy. </font></p>
<HR SIZE=2 COLOR=#3399CC>
<p class=grant><font class="textblack" color="#000000">Sources of funding: Various 
  pharmaceutical companies.</font></p>
<p class=reprint><font class="textblack" color="#000000">For correspondence: Dr. 
  F.H. Messerli, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, LA 70121, 
  USA. FAX 504-842-4220. </font><font class="textblack" color="#000000" size="2"></font></p>
<P CLASS="AbsFootn">*See <a href="Glossary2.html" target="_blank">Glossary</a> 
</p>
<META NAME="Table1"><HR SIZE=2 COLOR=#3399CC>
<P CLASS="AbsHd">Commentary</p>
<p class=cmtxt><font class="textblack" color="#000000">Achieving tight blood-pressure 
  control in patients with diabetes requires drug therapy, with most patients 
  needing combination drug therapy (1). The choice of agent has been complicated 
  by conflicting evidence of efficacy and safety. The review by Grossman and colleagues 
  shows that currently used agents are more effective than is placebo for lowering 
  cardiovascular risk in patients with diabetes and hypertension. </font></p>
<p class=cmtxt><font class="textblack" color="#000000">Does this mean that these 
  agents are equivalent? Differences among agents are better assessed in head-to-head 
  comparisons. The results of the review are consistent with a recently published 
  meta-analysis (2) that reviewed the same 4 randomized trials comparing ACE inhibitors 
  with calcium antagonists, diuretics, and Î²-blockers. In 3 trials, ACE inhibitors 
  lowered the risk for cardiovascular events (relative risk reduction [RRR] 51%, 
  CI 33 to 64) and all-cause mortality more than did other agents (RRR 62%, CI 
  13 to 62) with no effect on the risk for stroke. The fourth trial (the U.K. 
  Prospective Diabetes Study) may not have had sufficient power to show differences 
  between ACE inhibitors and Î²-blockers (3). These reports show that ACE inhibitors 
  are similar to, if not better than, other antihypertensive drug classes for 
  patients with diabetes. </font></p>
<p class=cmtxt><font class="textblack" color="#000000">Should ACE inhibitors be 
  used as first-line treatment in patients with diabetes and hypertension? Treatment 
  with ramipril in patients with diabetes and hypertension lowers cardiovascular 
  risk by 25% (CI 12 to 36) (4), a reduction beyond its antihypertensive effect. 
  This evidence supports the consideration of ACE inhibitors in all patients with 
  diabetes and hypertension. Whatever the choice of agent, patients with diabetes 
  and their clinicians should choose tight blood-pressure control. </font></p>
<p class=cmauth><font class="textblack" color="#000000">Victor M. Montori, MD</font></p>
<p class=cmauthaff><font class="textblack" color="#000000">Mayo Clinic</font></p>
<p class=cmauthaff><font class="textblack" color="#000000">Rochester, Minnesota, 
  USA</font><font class="textblack" color="#000000" size="2"></font></p>
<HR SIZE=2 COLOR=#3399CC>
<p class=refhd><font class="textblack" color="#000000">References</font></p>
<p class=ref id=ACPJC-2001-134-2-048-r1><font class="textblack" color="#000000">1. 
  <b>U.K. Prospective Diabetes Study Group.</b> Tight blood pressure control and 
  risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 
  38. BMJ. 1998;317:703-13. </font></p>
<p class=ref id=ACPJC-2001-134-2-048-r2><font class="textblack" color="#000000">2. 
  <b>Pahor M, Psaty BM, Alderman MH, et al.</b> Therapeutic benefits of ACE inhibitors 
  and other antihypertensive drugs in patients with type 2 diabetes. Diabetes 
  Care. 2000;23:888-92. </font></p>
<p class=ref id=ACPJC-2001-134-2-048-r3><font class="textblack" color="#000000">3. 
  <b>U.K. Prospective Diabetes Study Group.</b> Efficacy of atenolol and captopril 
  in reducing risk of macrovascular and microvascular complications in type 2 
  diabetes: UKPDS 39. BMJ. 1998;317:713-20. </font></p>
<p class=ref id=ACPJC-2001-134-2-048-r4><font class="textblack" color="#000000">4. 
  <b>Heart Outcomes Prevention Evaluation Study Investigators.</b> Effects of 
  ramipril on cardiovascular and microvascular outcomes in people with diabetes 
  mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-9. 
  </font><font class="textblack" color="#000000" face="arial, helvetica, sans-serif"> 
  </font></p>
<P CLASS="CmRef"><font class=textblack 
      face="arial, helvetica, sans-serif" color=#000000 size=2><font 
      class=pageboldgrn color=#009982 size=2><font 
      class=copyrightblue face="arial, sans-serif" color=#3399cc 
      size=1>Copyright Â©2001 American College of Physicians – American Society 
  of Internal Medicine</font> </font></font></p>
</BODY>
</HTML>
